WILMINGTON – Life science firm Pharmaceutical Product Development is preparing to gpossibly o public again.
The company founded by entrepreneur and philanthropist Fred Eshelman was acquired and taken private in 2011.
It employs some 23,000 people across 100 offices – including a large one in the Triangle – in 46 countries.
PPD said Tuesday it had filed a “draft registration statement” with the SEC stating interest in an initial public offering. The number of shares that would be offered and the price range “have not yet been determined,” PPD said in a statement.
No time line was specificed.
“The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions,” the company said.
In 2017, PPD raised $500 million in new capital, raising the company’s value to an estimated $9 billion.
Rumors circulated in late 2016 that the company might be sold.
More PPD headlines
Subsidiary of Wilmington-based PPD acquires global site business from Bioclinica
PPD group launches major dementia study, to include 30,000 people
